3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Hepatocellular
19
Carcinoma, Renal Cell
13
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Endometrial Neoplasms
6
Neoplasms
4
Biliary Tract Neoplasms
4
Neuroendocrine Tumors
3
Melanoma
3
Liver Neoplasms
3
Vulvar Neoplasms
2
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Brain Neoplasms
2
von Hippel-Lindau Disease
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Penile Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Lung Neoplasms
1
Kidney Neoplasms
1
Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
1
Interventions
Nivolumab
3
Cisplatin
3
atezolizumab
2
Irinotecan
2
Ipilimumab
2
Etoposide
2
Carboplatin
2
tivozanib
1
repotrectinib
1
niraparib
1
gallium Ga 68 dotatate
1
dostarlimab
1
cabozantinib
1
budigalimab
1
belinostat
1
Topotecan
1
Temozolomide
1
Specimen Handling
1
Radiosurgery
1
Radionuclide Imaging
1
Positron-Emission Tomography
1
Positron Emission Tomography Computed Tomography
1
Magnetic Resonance Spectroscopy
1
Leucovorin
1
Immunoglobulin G
1
IFL protocol
1
Fluorouracil
1
Disulfides
1
DLL3 protein, human
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Neuroendocrine
×
lenvatinib
×
90 days
×
Clear all
No trials found.